Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — Woodward Partners NZ Mid Cap Spotlight (April 2017)
10 slides from Aft Pharmaceuticals's conference presentation, Apr 12, 2017
Slide 1: AFT Pharmaceuticals Woodward Partners NZ Mid Cap Spotlight Presentation
For personal use only AFT PHARMACEUTICALS Woodward Partners NZ Mid Cap Spotlight Presentation 12 April 2017
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT to selected recipients in New Zealand. It is not prepared for any other purpose and must not be reproduced or provided to any person other than the intended recipient. It
Slide 3: Progress Update
PROGRESS UPDATE Countries that Maxigesic is licensed in – up from 98 at the end of 111 FY2016. Negotiations underway for North America (MX & US/CA to follow) & EU For personal use only 6 Countries that Maxigesic has launched and is sold in with at least 20 further launches expected during this FY201
Slide 4: Maxigesic Update
MAXIGESIC UPDATE Eastern Europe – launches UK – successfully launched pending Italy – successful launch and Nordics – planned launches in sales increasing significantly 2017 For personal use only Kuwait launch pending soon UAE – sales doubling in second year of sales HK– launch pending FY2018 Malays
Slide 5: Maxigesic Sales Progress to Date
MAXIGESIC SALES PROGRESS TO DATE Maxigesic Tablets Sold Per Year For personal use only 80 Millions 60 40 20 - FY2010 FY2011 FY2012 FY2013 FY2014 FY2015 FY2016 FY2017* • Maxigesic tablet sales for the FY2017 financial year are expected to increase to 74 million tablets per annum, representing a 339%
Slide 6: Maxigesic and AU Codeine Switch
MAXIGESIC AND AU CODEINE SWITCH CODEINE Market Research in AU ex MedPanel * and Market Data For personal use only • 13M Maxigesic tablet sales for the FY2017 financial year in AU. • 1Feb 2018 Codeine based OTC analgesics will be rescheduled to Rx • 750M tablets of Codeine OTC Analgesics used in AU •
Slide 7: NasoSURF Nebuliser
NASOSURF NEBULISER DRUG DELIVERY AND TREATMENT OF SINUS CONDITIONS For personal use only A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of chronic description sinusitis • To expand our existing allergy and hospital product ranges The NasoSU
Slide 8: Other Key Innovative Products
OTHER KEY INNOVATIVE PRODUCTS Products Status For personal use only Pascomer currently being developed, with an IND Application to be opened in US during FY2018 to enable clinical studies to be undertaken Successfully obtained ODD from FDA. EMA under application after successful meeting Pascomer (or
Slide 9: Summary Balance Sheet
SUMMARY BALANCE SHEET Restated Unaudited as at 30 Restated Unaudited as at 30 NZ$000's Sep 2016 Sep 2015 For personal use only ASSETS Current assets • AFT has maintained very Inventories 21,451 15,072 tight control of fixed Trade and other receivables 12,748 12,224 Cash and other equivalents 16,054
Slide 10: Summary of Near Term Plans
SUMMARY OF NEAR TERM PLANS Launch Maxigesic in new countries and increase sales For personal use only Advance Maxigesic registrations in licensed countries and in North America Complete remaining clinical studies of Maxigesic products over FY2018 NasoSURF – complete first clinical trials and first C
AFT Pharmaceuticals — Woodward Partners NZ Mid Cap Spotlight (April 2017) on 6ix